CiMaas, a biotech company based in Maastricht, develops Natural Killer (NK) cell therapies for cancer treatment. Founded as a spin-off from Maastricht University, the company focuses on safe, effective immunotherapies for metastatic and late-stage cancers.
We invested in CiMaas through 819 Evergreen Fund I.
Deventer, 6 November 2025 – Travel company Tioga Tours, a specialist in tailor-made trips to America and Canada, is entering into a strategic partnership with 819 Capital Partners. Founder and owner Paul Backer will remain involved as a minority shareholder and continue to lead the company. Over the past years, Tioga Tours has grown into the market leader in hotel and motorhome travel to the United States and Canada. The company aims to continue its...
Continue readingDeventer, 9 October 2025 – 819 Capital Partners announces the launch of 819 Seed Fund, a new €9 million fund established with support from the Netherlands Enterprise Agency (RVO). 819 Seed Fund is designed to address the growing demand for venture capital among early-stage deep tech and med tech companies, offering ticket sizes from €250k - €1.5M. Its mission is to help entrepreneurs develop, validate, and scale breakthrough technologies in the Netherlands. By investing at...
Continue reading